Aktuellt
SENASTE
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier today. Overall, the report did not contain any significant surprises and was in line with our expectations. Accordingly, we reiterate our fair value range with a base case valuation of SEK13.5 as we look forward to the readouts from the company's three ongoing clinical trials expected later this year.
LÄS MER
